Improved drug bioavailability

Improved drug bioavailability is a pharmacological objective rather than a discrete biological target such as a receptor or enzyme. It represents the enhancement of the rate and extent to which an active drug ingredient reaches the systemic circulation, typically denoted by the pharmacokinetic parameter 'F' (Price & Patel, 2023). In drug development, low bioavailability is often a hurdle caused by poor aqueous solubility, low membrane permeability, or extensive first-pass metabolism by hepatic enzymes and intestinal transporters like P-glycoprotein (NIH, 2023). Strategies to optimize this parameter include the use of prodrugs, nanocarriers, lipid-based delivery systems, and micronization to ensure that therapeutic concentrations are achieved at the site of action (Merck Manual, 2022). While not a target itself, achieving optimal bioavailability is critical for the efficacy and safety profile of any systemic therapeutic agent across all medical disciplines.

Other names

BioavailabilityDrug absorption enhancementSystemic availabilityPharmacokinetic F-valueF-factor

Not applicable as this is a pharmacokinetic parameter. Bioavailability refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. Methods to improve it include enhancing solubility (e.g., via lipid-based formulations), improving permeability (e.g., via prodrugs), and reducing first-pass metabolism (e.g., via enzyme inhibition).